10 Best Mid-Cap Healthcare Stocks To Buy Now

6. Structure Therapeutics Inc. (NASDAQ:GPCR)

Hedge Fund Holders: 43 

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company developing oral drugs for chronic diseases. It focuses on small molecules targeting G protein-coupled receptors (GPCRs) for metabolic and pulmonary conditions. Their lead candidate addresses obesity and type 2 diabetes. The company earns revenue through partnerships, licensing, and future drug sales.

A significant catalyst for Structure Therapeutics Inc. (NASDAQ:GPCR) is its development of oral obesity drugs, particularly GSBR-1290. This compound has shown potential to challenge established players like Novo Nordisk and Eli Lilly in the rapidly growing obesity treatment market.

Structure Therapeutics Inc. (NASDAQ:GPCR) has four approved products, including Crysvita for X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii for mucopolysaccharidosis VII, Dojolvi for long-chain fatty acid oxidation disorders, and Evkeeza for homozygous familial hypercholesterolemia.

As of Q2 2024, around 43 hedge fund holders held stakes in the stock with a Strong Buy rating based on 7 Wall Street Analysts. The average price target is $85.57, with a high of $100.00 and a low of $65.00, reflecting a 124.42% increase from the current price of $38.13.